{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:25:14Z","timestamp":1793395514024,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008130","name":"Helsinn Therapeutics US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106306","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T19:36:45Z","timestamp":1773776205000},"page":"106306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase III trial of infigratinib versus gemcitabine\/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-8054","authenticated-orcid":false,"given":"G.K.","family":"Abou-Alfa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-214X","authenticated-orcid":false,"given":"I.","family":"Borbath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-3038","authenticated-orcid":false,"given":"S.","family":"Roychowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"A.","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.T.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5952-7674","authenticated-orcid":false,"given":"C.","family":"Tama\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-2144","authenticated-orcid":false,"given":"D.M.","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.F.","family":"van Veenhuyzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Freas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Solanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.esmoop.2026.106306_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.106306_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.esmoop.2026.106306_bib3","first-page":"1","article-title":"Cancer review: cholangiocarcinoma","volume":"14","author":"Ghouri","year":"2015","journal-title":"J Carcinog"},{"key":"10.1016\/j.esmoop.2026.106306_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106306_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106306_bib6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines\u00ae Insights: Biliary Tract Cancers, Version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10391","key":"10.1016\/j.esmoop.2026.106306_bib7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106306_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.106306_bib9","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106306_bib10","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106306_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729241","article-title":"Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma","volume":"24","author":"Chun","year":"2017","journal-title":"Cancer Control"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106306_bib12","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106306_bib13","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106306_bib14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106306_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106306_bib16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106306_bib17","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.esmoop.2026.106306_bib18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106306_bib19","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106306_bib20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"issue":"suppl 9","key":"10.1016\/j.esmoop.2026.106306_bib21","article-title":"Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)","volume":"33","author":"Valle","year":"2022","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106306_bib22","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106306_bib23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106306_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106306_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106306_bib26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"30","key":"10.1016\/j.esmoop.2026.106306_bib27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106306_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106306_bib30","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106306_bib31","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/oncolo\/oyac139","article-title":"An expert, multidisciplinary perspective on best practices in biomarker testing in intrahepatic cholangiocarcinoma","volume":"27","author":"Madoff","year":"2022","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106306_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cancers14020392","article-title":"Optimizing the diagnosis and biomarker testing for patients with intrahepatic cholangiocarcinoma: a multidisciplinary approach","volume":"14","author":"Cho","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.106306_bib33","series-title":"Truseltiq (infigratinib) capsules, for oral use. Prescribing information","year":"2021"},{"key":"10.1016\/j.esmoop.2026.106306_bib34","series-title":"Pemazyre\u00ae (pemigatinib) tablets, for oral use. Prescribing information","year":"2022"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106306_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106306_bib36","series-title":"Lytgobi\u00ae (futibatinib) tablets, for oral use. Prescribing information","year":"2022"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926002486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926002486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:33:11Z","timestamp":1776699191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926002486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926002486"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106306","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase III trial of infigratinib versus gemcitabine\/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106306"}}